Due to the unique healthcare access environment in Taiwan Province, the public can conveniently purchase a wide variety of over-the-counter (OTC) medications from neighborhood community pharmacies, including cold syrups, remedies, and cough syrups. However, busy parents returning home exhausted from work sometimes reach for these convenient OTC solutions for their children, overlooking the hidden medical hazards these medications can pose to young bodies.

Experts from the Food and Drug Administration (TFDA) under the Ministry of Health and Welfare of the Republic of China urge caution before administering medications containing codeine to minors. Many developed nations have enacted strict regulatory prohibitions banning the use of OTC drugs containing codeine in children under 12 years of age.

Official surveys reveal that several commercial cough syrups and cold remedies contain “Codeine”, an opioid analgesic and antitussive derived from opium extracts and chemical synthesis. At low doses, it functions as an OTC antitussive commonly found in pharmacy-shelf cough syrups; at higher doses, it serves as a prescription analgesic to manage mild to moderate pain and is classified as a controlled substance. Improper administration of codeine can trigger acute opioid toxicity, presenting with symptoms such as respiratory depression, profound lethargy, hypotonia, altered consciousness, miosis (pinpoint pupils), nausea, vomiting, constipation, and anorexia. In severe instances, it can induce life-threatening respiratory arrest and death.

Notably, once codeine enters the body, hepatic metabolism converts it into active metabolites (including morphine) that circulate in the bloodstream. In pediatric patients—especially ultra-rapid metabolizers—this drastically amplifies the risk of opioid toxicity, leading to dyspnea and dangerously depressed respiration in young children and breastfed infants. Furthermore, adolescents between the ages of 12 and 18 who suffer from compromised respiratory function are strongly advised against using codeine-containing medications.

In light of multiple international cases of severe respiratory depression in children, the US Food and Drug Administration (FDA) issued formal safety alerts in April 2017 restricting codeine use in children under 12 years old and nursing mothers.

Given that numerous safer non-opioid antitussive alternatives exist, children under 12 do not require codeine-based therapeutics. In response, after reviewing domestic and international pharmacovigilance data, our country’s TFDA formally mandated in September 2017 that prescription medications containing codeine be evaluated with extreme caution when prescribed to children under 12, while OTC preparations containing codeine are strictly prohibited for children under 12. Domestic pharmaceutical manufacturers were instructed to revise package inserts, package warnings, indications, and contraindications to safeguard pediatric safety and clear up ambiguity for healthcare professionals and the public.

✦ Independent Journalism · Reader Support ✦

Support Independent Perspectives & In-Depth Insights

Every thoughtful analysis and candid critique comes from our dedication to truth and quality. We choose not to follow sensational algorithms or clickbait headlines.

Sustaining independent research requires reader support. Make a one-time or monthly contribution, securely processed by Google.

Payments secured by Google · Manage or cancel anytime in your Google Account